These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28576323)

  • 1. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring.
    Ricklin D; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():10-21. PubMed ID: 28576323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
    Asif A; Nayer A; Haas CS
    J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.
    Volokhina EB; van de Kar NC; Bergseth G; van der Velden TJ; Westra D; Wetzels JF; van den Heuvel LP; Mollnes TE
    Clin Immunol; 2015 Oct; 160(2):237-43. PubMed ID: 26111482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
    Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future pharmacologic complement inhibitors.
    Risitano AM
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New Complement Therapeutics in Complement-Related Diseases].
    Wakamiya N; Ohtani K; Hidaka Y; Inoue N
    Brain Nerve; 2019 Jun; 71(6):555-564. PubMed ID: 31171752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing.
    Tampaki A; Gavriilaki E; Varelas C; Anagnostopoulos A; Vlachaki E
    Blood Rev; 2021 Jul; 48():100805. PubMed ID: 33504459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the management of atypical hemolytic uremic syndrome.
    Cataland SR
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):537-9. PubMed ID: 23073053
    [No Abstract]   [Full Text] [Related]  

  • 13. Complement inhibitors are not useful in secondary hemolytic uremic syndromes.
    Duineveld C; Wetzels JFM
    Kidney Int; 2019 Oct; 96(4):829-833. PubMed ID: 31543154
    [No Abstract]   [Full Text] [Related]  

  • 14. The renaissance of complement therapeutics.
    Ricklin D; Mastellos DC; Reis ES; Lambris JD
    Nat Rev Nephrol; 2018 Jan; 14(1):26-47. PubMed ID: 29199277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Atypical hemolytic uremic syndrome caused by primary complement defects].
    Reusz G
    Orv Hetil; 2018 Jun; 159(23):929-936. PubMed ID: 29860884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An international consensus approach to the management of atypical hemolytic uremic syndrome in children.
    Loirat C; Fakhouri F; Ariceta G; Besbas N; Bitzan M; Bjerre A; Coppo R; Emma F; Johnson S; Karpman D; Landau D; Langman CB; Lapeyraque AL; Licht C; Nester C; Pecoraro C; Riedl M; van de Kar NC; Van de Walle J; Vivarelli M; Frémeaux-Bacchi V;
    Pediatr Nephrol; 2016 Jan; 31(1):15-39. PubMed ID: 25859752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement Inhibitors in Clinical Trials for Glomerular Diseases.
    Zipfel PF; Wiech T; Rudnick R; Afonso S; Person F; Skerka C
    Front Immunol; 2019; 10():2166. PubMed ID: 31611870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.